Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma

Treatment Phase: Continuing treatment

Clinical criteria:

  • Patient must have received PBS-subsidised treatment with this drug for this PBS indication,

AND

  • Patient must have demonstrated a response to treatment with this drug if treatment is continuing beyond 6 months of treatment for the first time,

AND

  • The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; OR

  • The treatment must be in combination with peginterferon alfa-2a only if used in combination with another drug,

AND

  • Patient must be receiving the medical service as described in item 14249 of the Medicare Benefits Schedule.

Treatment criteria:

  • Must be treated by a haematologist; OR

  • Must be treated by a medical physician working under the supervision of a haematologist.

A response, for the purposes of administering this continuing restriction, is defined as attaining a reduction of at least 50% in the overall skin lesion score from baseline, for at least 4 consecutive weeks. Refer to the Product Information for directions on calculating an overall skin lesion score. The definition of a clinically significant reduction in the Product Information differs to the 50% requirement for PBS-subsidy. Response only needs to be demonstrated after the first six months of treatment

Note

The maximum quantity and maximum number of repeats are based on the following treatment protocol: one day of treatment per week for six weeks, then every two weeks for 12 weeks, then monthly thereafter. This differs from the Product Information. Requests for increased maximum quantities/maximum repeats will not be considered.